

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

Recombinant Anti-CPT1A antibody [EPR21843-71-2F]

RRID:AB_2864319

Type: Antibody

Proper Citation

(Abcam Cat# ab234111, RRID:AB_2864319)

Antibody Information

URL: http://antibodyregistry.org/AB_2864319

Proper Citation: (Abcam Cat# ab234111, RRID:AB_2864319)

Target Antigen: CPT1A

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, IHC-P, Flow Cyt

Antibody Name: Recombinant Anti-CPT1A antibody [EPR21843-71-2F]

Description: This recombinant targets CPT1A

Target Organism: rat, mouse, human

Clone ID: EPR21843-71-2F

Antibody ID: AB_2864319

Vendor: Abcam

Catalog Number: ab234111

Record Creation Time: 20260408T215514+0000

Record Last Update: 20260408T215518+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CPT1A antibody [EPR21843-71-2F].

No alerts have been found for Recombinant Anti-CPT1A antibody [EPR21843-71-2F].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Weber JL, et al. (2026) De novo pyrimidine synthesis controls germinal center B cell and plasma cell fates and systemic autoimmunity. *Cell reports*, 45(7), 117587.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. *Cancer research*, 86(13), 3194.

Desmarais F, et al. (2025) A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(20), e71172.

Wei X, et al. (2024) Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages. *Cell metabolism*, 36(10), 2281.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. *Cell reports*, 42(11), 113424.

Ding S, et al. (2022) Astilbin Activates the Reactive Oxidative Species/PPAR γ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1. *Frontiers in pharmacology*, 13, 848957.

Wei X, et al. (2020) Reducing NADPH Synthesis Counteracts Diabetic Nephropathy through Restoration of AMPK Activity in Type 1 Diabetic Rats. *Cell reports*, 32(13), 108207.